Harvard Bioscience (NASDAQ:HBIO) Shares Pass Below 200-Day Moving Average of $3.53

Harvard Bioscience, Inc. (NASDAQ:HBIO) shares crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $3.53 and traded as low as $2.80. Harvard Bioscience shares last traded at $2.88, with a volume of 109,200 shares.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered Harvard Bioscience from a “buy” rating to a “hold” rating in a research note on Thursday, May 9th.

Harvard Bioscience Stock Down 1.7 %

The company has a quick ratio of 0.94, a current ratio of 2.05 and a debt-to-equity ratio of 0.48. The business has a 50-day simple moving average of $3.01 and a two-hundred day simple moving average of $3.53. The stock has a market capitalization of $125.08 million, a P/E ratio of -14.40 and a beta of 1.30.

Harvard Bioscience (NASDAQ:HBIO) last posted its earnings results on Thursday, August 8th. The medical instruments supplier reported ($0.03) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.06). The firm had revenue of $23.10 million during the quarter, compared to the consensus estimate of $29.91 million. Harvard Bioscience had a negative return on equity of 2.70% and a negative net margin of 10.56%. Equities research analysts forecast that Harvard Bioscience, Inc. will post 0.11 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO James W. Green bought 10,000 shares of the business’s stock in a transaction dated Thursday, June 13th. The stock was bought at an average price of $2.91 per share, for a total transaction of $29,100.00. Following the completion of the purchase, the chief executive officer now owns 3,111,091 shares of the company’s stock, valued at approximately $9,053,274.81. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Harvard Bioscience news, CEO James W. Green bought 10,000 shares of the firm’s stock in a transaction dated Thursday, June 13th. The shares were bought at an average price of $2.91 per share, for a total transaction of $29,100.00. Following the completion of the acquisition, the chief executive officer now owns 3,111,091 shares of the company’s stock, valued at $9,053,274.81. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO James W. Green bought 20,000 shares of the stock in a transaction dated Thursday, June 6th. The stock was acquired at an average price of $3.07 per share, with a total value of $61,400.00. Following the completion of the purchase, the chief executive officer now owns 3,101,091 shares of the company’s stock, valued at approximately $9,520,349.37. The disclosure for this purchase can be found here. Insiders own 9.00% of the company’s stock.

Hedge Funds Weigh In On Harvard Bioscience

A number of institutional investors have recently modified their holdings of HBIO. AMH Equity Ltd raised its position in shares of Harvard Bioscience by 7.5% during the first quarter. AMH Equity Ltd now owns 2,324,200 shares of the medical instruments supplier’s stock worth $9,855,000 after acquiring an additional 161,307 shares during the last quarter. Vanguard Group Inc. increased its position in Harvard Bioscience by 2.4% in the first quarter. Vanguard Group Inc. now owns 2,152,147 shares of the medical instruments supplier’s stock worth $9,125,000 after purchasing an additional 49,576 shares during the period. Heartland Advisors Inc. raised its holdings in Harvard Bioscience by 2.6% during the 1st quarter. Heartland Advisors Inc. now owns 889,133 shares of the medical instruments supplier’s stock worth $3,770,000 after purchasing an additional 22,666 shares during the last quarter. Meros Investment Management LP lifted its position in Harvard Bioscience by 1.6% during the 2nd quarter. Meros Investment Management LP now owns 835,213 shares of the medical instruments supplier’s stock valued at $2,380,000 after purchasing an additional 13,421 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in shares of Harvard Bioscience by 6.1% in the 2nd quarter. Renaissance Technologies LLC now owns 745,278 shares of the medical instruments supplier’s stock valued at $2,124,000 after purchasing an additional 42,800 shares during the last quarter. 80.87% of the stock is owned by institutional investors.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.